AMA. Yu. Ma-Van-De

A. Yu. Ma-Van-De

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. Yu. Ma-Van-De has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NEURAL NETWORK ANALYSIS AS A WAY TO ASSESS SOME PATHOGENETIC ASPECTS OF NEUROINFLAMMATION IN HYPERTENSIVE DISEASE

    by Алексей Юрьевич Ма-Ван-Дэ, Елена Викторовна Фефелова, Yuri A. Shirshov, Василина Денисовна Ма-Ван-Дэ, Artur S. Emelyanov

    Highlights Cardiovascular diseases are the leading cause of death in the population. The most common cardiovascular disease is hypertension, which can lead to damage to target organs, including the brain. Several studies have examined the role of specific neuroinflammatory molecules and tumor necrosis factor family proteins in the progression and outcome of vascular-related cerebral damage. The article highlights the possibilities of neural network analysis, which can be used to determine the ranked contribution of certain biomarkers to the pathogenesis of neuroinflammation that develops in hypertension.  AbstractBackground. Hypertensive disease is accompanied by involvement of target organs, including the brain, in the pathological process, leading to the development of acute and chronic cerebrovascular diseases. The development of modern methods for predicting the development and course of angio-cerebral pathology can be used to create new methods for managing patients at risk.Aim. Using the capabilities of neural network analysis, we determined the ranked contribution of biomarkers of neuroinflammation and proteins of the tumor necrosis factor family to the pathogenesis of neuroinflammation in the context of hypertension.Methods. The study involved 80 participants. The control group consisted of healthy individuals. The first group included patients with stage II–III hypertension, achieved target blood pressure levels, and a 3–4 risk of developing cardiovascular complications. The second group consisted of patients with stage II–III hypertension, unachieved target blood pressure levels, and a 3–4 risk of developing cardiovascular complications. Group 3 included patients with a verified diagnosis of ischemic (atherothrombotic) stroke. The data obtained from the study were used to train a multilayer perceptron and create a mathematical model that determines the ranked contribution of biomarkers of neuroinflammation and proteins of the tumor necrosis factor family to the pathogenesis of neuroinflammation in the context of hypertension.Results. According to the results of the conducted multiplex analysis and statistical data processing, similar shifts in the neuroimmune status were identified in both patients with ischemic stroke and individuals with hypertension. Modern developments in the field of predicting the development and course of angiocerebral pathology can be used to create new methods for managing patients at risk.Conclusion. The data obtained as a result of the conducted study indicate changes in the neuroimmune status of patients with hypertension. It is noteworthy that the content of biomarkers associated with neuroinflammation in patients with unattained target blood pressure levels is as close as possible to that of patients with ischemic stroke. At the same time, in the group of patients with achieved target blood pressure levels, there is also a shift in the studied indicators, but to a lesser extent, which may indicate the presence of a neuroinflammatory process that is present even in the presence of antihypertensive therapy and blood pressure control. The mathematical model developed using neural network analysis allowed us to determine the ranked contribution of the studied parameters to the pathogenesis of neuroinflammation in patients with hypertension. These results can be further used for a more personalized approach to patient treatment by influencing specific aspects of the pathogenesis, thereby moderating the ongoing process and influencing the future course of the disease.


  • Open Access

    Dynamics of concentration of neuroinflammatory molecules in ischemic stroke

    by A. Yu. Ma-Van-De, E. V. Fefelova

    The aim of the research. To determine the level of transforming growth factor-β (TGF-β), brain-derived neurotrophic factor (BDNF) and nerve growth factor (β-NGF) in the blood serum of patients with ischemic stroke (atherothrombotic subtype) in the acute period and over time.Materials and methods. The study involved 60 people (50% men and 50% women), who were divided into three groups of 20 people. Group I – healthy individuals; Group II – patients with hypertensive crisis without signs of target organ damage (uncomplicated hypertensive crisis); III – patients with a verified diagnosis of atherothrombotic ischemic stroke that developed against the background of a hypertensive crisis. Patients of groups I, II and III were comparable by gender, age, II and III also by comorbid background. The average age of patients was 56,3 (48,8; 63,3) years.Results. Based on the results of the study, it was found that in individuals with uncomplicated hypertensive crisis, as well as in patients with ischemic stroke, an increase in the concentration of BDNF and β-NGF in the blood serum was recorded on the first day. TGF-β1 indicators changed only in patients with ischemic stroke. In the group of patients with ischemic stroke, an increase in BDNF, β-NGF, TGF-β1 indicators was observed from the first day from the onset of the disease and persisted throughout the study period. Positive correlations were found between the concentration of BDNF and systolic and diastolic blood pressure (BP), as well as between the concentration of β-NGF and the number of points on the NIHSS scale, SBP and DBP levels.Conclusion. The registered increase in the concentration of BDNF, β-NGF in patients with hypertensive crisis may indicate the activation of microglia due to damage to the brain as a target organ, even in the absence of neurological symptoms.

  • Open Access

    Dynamic indices of fractalkine in ischemic stroke

    by A. Yu. Ma-Van-De, E. V. Fefelova, Yu. A. Shirshov, V. D. Ma-Van-De

    Background. The problem of a personalized approach to patients with ischemic stroke does not lose its relevance. Research is being conducted aimed at searching for points of application in the pathogenesis of cerebral infarction and the possibility of influencing them in order to have a positive impact on the recovery prognosis of patients.The aim of the work. To study the level of fractalkine (FKN) in the blood serum of patients with ischemic stroke (atherothrombotic subtype) in dynamics. The data obtained in the future can serve as the basis for the possible use of fractalkine as one of the treatment options for patients with acute cerebral ischemia.Materials and methods. Sixty people took part in the study. Group I (control) – healthy people; Group II – patients with hypertensive crisis without signs of acute changes in target organs; Group III – patients with atherothrombotic pathogenetic subtype of ischemic stroke on the background of hypertensive crisis.Results. It was revealed that the level of fractalkine in patients with hypertensive crisis, and in patients on the first day after the development of ischemic stroke, was 3.2 times higher than in the control group (p < 0.001). The fractalkine content in the blood serum of patients with ischemic stroke remained high for ten days. The highest level was recorded on days 4–5 from the onset of the disease and exceeded the initial level by 27.5 % (p < 0.001). Positive correlations were established between fractalkine indicators and indicators of the NIHSS (National Institutes of Health Stroke Scale) and Rankin scales, and blood pressure (p < 0.001).Conclusion. Studying the role of fractalkine in the pathogenesis of cerebral infarction remains a promising direction. The results obtained with further research in this area may become the basis for the subsequent development of fundamentally new approaches in the treatment of patients with acute cerebral events.

  • Open Access

    DIFFICULTIES IN DIFFERENTIAL DIAGNOSTICS OF DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM

    by A. N. Vlasova, A. Yu. Ma-Van-De, Y A. Shirshov, D. N. Guzhov, V. D. Ma-Van-De

    Demyelinating diseases of the central nervous system are a group of autoimmune inflammatory diseases of the central nervous system (CNS) characterized by the formation of multiple foci of demyelination in the white matter of the brain and spinal cord. The clinic is quite polymorphic and may include various isolated and combined neurological syndromes. The commonality of pathogenetic reactions that underlie this nosological group determines their rather similar clinical picture, which can lead to difficulties in diagnosis. This article presents an analysis of a clinical case of demyelinating disease in a young 18-year-old patient. The peculiarity was that the disease arose at a fairly early age, was accompanied by severe rapidly progressive neurological symptoms due to the simultaneous involvement of the white matter of the brain and spinal cord in the pathological process.

  • Open Access

    ANTIEPILEPTIC DRUG EFFICACY IN CERTAIN GENETIC TYPES OF CHILDHOOD EPILEPSY

    by N. A. Marueva, Y. A. Shirshov, T. N. Shil'NIkova, A. Y. Ma-Van-De

    Objective: we aimed to study antiepileptic drug efficacy in achieving seizure remission in certain genetic types of childhood epilepsy.Materials and methods. The authors studied 240 patients aged from 1 month to 18 years with epilepsy between 2019 and 2023. Children with genetic forms of epilepsy accounted for 69 (28,8%). In this group, remission was achieved in 13 (18,8%) of patients. Among them, there were 13 children (%) with certain forms of genetic epilepsy aged 5 to 4 (average 10 ± years), with 7 (53,8%) being girls and 6 (46,2%) being boys. There were 7 (53,8%) children with generalized epilepsy, including 5 (30,8%) cases of childhood absentee epilepsy. 5 (38,5%) patients had focal epilepsy, all of them had self-controlling epilepsy with central temporal adhesions. The study included one patient with an unspecified type of epilepsy (7.7%).Results. The duration of remission ranged from 6 months to 7 years 2 months (me – 3 years 8 months). 11 children (84,6%) were in stable remission for 1 year or longer. Complete clinical electroencephalographic remission was observed in 7 (53,9%) cases. In other cases, regional and diffuse epileptiform activity was recorded in 3 (75,0%) and 1 (25,0%) case, respectively. Remission was achieved in 5 children (38,5%) who were taking levetiracetam, 6 subjects (46,1%) – valproic acid, 1 person – carbamazepine (7,7%). Persistent remission was registered in 4 children (36,3%) who were prescribed levetiracetam, 5 children (45,4%) taking valproic acid and 1 person (9 %) who was administered carbamazepine. 1 person (7,7%) was in stable remission after discontinuation of the antiepileptic drug.Conclusion. Most of the children with certain types of genetic epilepsy under the treatment with antiepileptic drugs were in stable seizure remission. More than half of those observed were in a complete clinical electroencephalographic remission. Predominantly, seizure remission occurred with the administration of valproic acid and levetiracetam, with the same frequency in generalized and focal types of genetic epilepsy.

  • Open Access

    THE ROLE OF INDIVIDUAL NEUROINFLAMMATION MOLECULES IN PATHOGENESIS ISCHEMIC STROKE. PART II

    by A. Yu. Ma-Van-De, E. V. Fefelova, Y. A. Shirshov, Н. А.. Маруева

    The problem of cerebrovascular diseases, in particular acute cerebrovascular accident, does not lose its relevance. Despite the primary and secondary prevention of cardiovascular diseases, the incidence of ischemic stroke among the population of the Russian Federation remains high. A well-established system of routing patients with acute vascular accidents and a multidisciplinary approach to treatment do not always guarantee a satisfactory result. The widespread prevalence of the disease, a high degree of disability and mortality, a decrease in the age of patients, economic losses associated with the rehabilitation of patients and their long-term disability dictate the need to find new and effective approaches to the diagnosis and treatment of this condition.Currently conducted studies are aimed at studying the pathogenetic cascade of reactions that occur at the time of acute cerebral ischemia, in order to develop adjuvant therapy. Based on the results obtained, additional options are being developed in the treatment and further rehabilitation of patients. The presented literature review collects and analyzes current data on the problem of ischemic stroke. The role of individual molecules of the tumor necrosis factor family, which are directly involved in the development and course of cerebral infarction, but also affect the further prognosis of survival and recovery of patients, is considered.

  • ISCHEMIC STROKE AS A GENETICAL DISEASE

    by A. Yu. Ma-Van-De, Yu. A. Vitkovsky

    Ишемический инсульт является мультифакториальным заболеванием, патогенез которого тесно связан с генетической предрасположенностью. Результаты проведенных исследований свидетельствуют о повышенном риске развития ишемического инсульта при наличии отягощённого семейного анамнеза. Установлено, что развитие острой церебральной ишемии в возрасте до 65 лет повышает риск возникновения острого нарушения мозгового кровообращения у ближайших родственников в 4 раза. Также известно, что инсульт, возникший в молодом возрасте, в большей степени связан с носительством различных генетических полиморфизмов, нежели с наличием факторов сердечно-сосудистого риска. В обзоре литературы представлены современные данные по острой цереброваскулярной патологии и ее связи с носительством различными полиморфных вариантов генов: ренин-ангиотензин-альдостероновой системы (РААС), генов, регулирующих функцию эндотелия, фолатный обмен, ионные...

  • IDIOPATHIC AUTOIMMUNE ENCEPHALITIS WITH ANTIBODIES TO NMDA RECEPTORS

    by Yu. A. Shirshov, A.Yu. Ma-Van-De, N. A. Marueva, A. D. Baldanshirieva


  • EPIDEMIOLOGICAL ASPECTS AND RISK FACTORSOF ISCHEMIC STROKE DEVELOPMENT (REVIEW OF THE LITERATURE)

    by A. Yu. Ma-Van-De, Yu. A. Vitkovsky, Yu. A. Shirshov

    Цереброваскулярные заболевания (ЦВЗ) являются главной причиной инвалидизации и смертности взрослого населения в Российской Федерации, США и странах Европы. Наиболее тяжёлой формой ЦВЗ является острое нарушение мозгового кровообращения (ОНМК). Несмотря на значительные успехи в организации медицинской помощи пациентам, которые перенесли острую сосудистую катастрофу, смертность от данной патологии в Российской Федерации остаётся одной из самых высоких в мире. Ишемический инсульт - это мультифакториальное заболевание, в основе которого лежат факторы риска, их коррекция достоверно снижает частоту возникновения церебральной ишемии. В обзоре литературы представлены современные эпидемиологические данные по цереброваскулярной патологии, освещена патогенетическая классификация ишемического инсульта, рассматриваются основные факторы риска его...